60
Treatment
10.1. Management of Comorbidities in Patients With HF
COR LOE
Recommendations
Management of Anemia or Iron Deficiency
2a B-R 1. In patients with HFrEF and iron deficiency with or without
anemia, intravenous iron replacement is reasonable to improve
functional status and QOL.
3: Harm B-R 2. In patients with HF and anemia, erythropoietin-stimulating
agents should not be used to improve morbidity and
mortality.
Management of Hypertension
1 C-LD 3. In patients with HFrEF and hypertension, uptitration
of GDMT to the maximally tolerated target dose is
recommended.
Management of Sleep Disorders
2a C-LD 4. In patients with HF and suspicion of sleep-disordered
breathing, a formal sleep assessment is reasonable to confirm
the diagnosis and differentiate between obstructive and
central sleep apnea.
2a B-R 5. In patients with HF and obstructive sleep apnea, continuous
positive airway pressure may be reasonable to improve sleep
quality and decrease daytime sleepiness.
3: Harm B-R 6. In patients with NYHA class II to IV HFrEF and central sleep
apnea, adaptive servo-ventilation causes harm.
Management of Diabetes
1 A 7. In patients with HF and type 2 diabetes, the use of SGLT2i is
recommended for the management of hyperglycemia and to
reduce HF-related morbidity and mortality.
10. Comorbidities in Patients With HF
